Skip to main content
Signal8

Nordicus Partners Corporation Corporate Update

$NORDPress releaseJun 15, 2026, 1:36 PM ET

Nordicus Partners reported positive preclinical efficacy for its lead asset QR-01 in two animal models of periodontitis, including reduced bone loss confirmed by micro-CT. The company plans to initiate Phase IIa clinical trials for QR-01 in patients at the University of Copenhagen in the first half of 2027. Subsidiary Bio-Convert received a toxicity waiver from the Danish Medicines Agency for QR-02 (targeting oral leukoplakia) and expects GMP manufacturing completion by December 2026, with Phase IIa trials also slated for H1 2027.

Key figures

Qr01 trial start
H1 2027
Qr02 trial start
H1 2027
Olk conversion rate
30%
Qr02 gmp completion
December 2026

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    NORD: Nordicus Partners Corporation Corporate Update — AI Analysis | Signal8